The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Seminars in Medicine of the Beth Israel Deaconess Medical Center
PreviousPrevious
Volume 336:633-640 February 27, 1997 Number 9
NextNext

Insulin-Like Growth Factors
Derek Le Roith, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
The insulin-like growth factors (IGFs) participate in the growth and function of almost every organ in the body.1 Because of the wide range of their biologic effects and their therapeutic potential in a variety of clinical disorders, the IGFs have become the focus of research by an increasing number of investigators.2,3,4 The object of this seminar is to review the clinical aspects of the IGFs, including their potential therapeutic value, and to discuss briefly their structure, synthesis, regulation, and physiologic role.

Basic Biochemistry and Physiologic Functions

Structure and Synthesis

The three peptide hormones, or growth factors, in the IGF family — insulin, IGF-I, and IGF-II — have approximately . . . [Full Text of this Article]

Physiologic Role and Mechanism of Action

Regulation and Differentiation of Function

Tissue IGFs

Pathologic Conditions Associated with Alterations in the IGF System

IGF-I

IGF-II

IGF-I as a Therapeutic Agent

Growth Hormone Insensitivity Syndrome

Insulin Resistance and Diabetes Mellitus

            Severe Insulin Resistance

            Insulin-Dependent Diabetes Mellitus

            Non-Insulin-Dependent Diabetes Mellitus

Side Effects of Short-Term IGF-I Administration

Side Effects of Multiple Subcutaneous Doses of IGF-I

Conclusions

Discussion


Source Information

From the Diabetes Branch, National Institutes of Health, Rm. 85235A, Bldg. 10, Bethesda, MD 20892-1770, where reprint requests should be addressed to Dr. Le Roith.

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.